Advertisement

Nonsense-Mediated mRNA Decay and Cystic Fibrosis

  • Liat Linde
  • Batsheva KeremEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 741)

Abstract

Approximately one-third of the alleles causing genetic diseases carry premature termination codons (PTCs). Therapeutic approaches for mutations generating in-frame PTCs are aimed at promoting translational readthrough of the PTC, to enable the synthesis and expression of full-length functional proteins. Interestingly, readthrough studies in tissue culture cells, mouse models, and clinical trials revealed a wide variability in the response to the readthrough treatments. The molecular basis for this variability includes the identity of the PTC and its sequence context, the chemical composition of the readthrough drug, and, as we showed recently, the level of PTC-bearing transcripts. One post-transcriptional mechanism that specifically regulates the level of PTC-bearing transcripts is nonsense-mediated mRNA decay (NMD). We have previously shown a role for NMD in regulating the response of CF patients carrying CFTR PTCs to readthrough treatment. Here we describe all the protocols for analyzing CFTR nonsense transcript levels and for investigating the role of NMD in the response to readthrough treatment. This includes inhibition of the NMD mechanism, quantification of CFTR nonsense transcripts and physiologic NMD substrates, and analysis of the CFTR function.

Key words

Premature termination codons nonsense-mediated mRNA decay readthrough gentamicin PTC124 

References

  1. 1.
    Frischmeyer, P. A., and Dietz, H. C. (1999) Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8, 1893–1900.PubMedCrossRefGoogle Scholar
  2. 2.
    Hirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., Hwang, S. et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J. Clin. Pharmacol. 47, 430–444.PubMedCrossRefGoogle Scholar
  3. 3.
    Linde, L., and Kerem, B. (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 24, 552–563.PubMedCrossRefGoogle Scholar
  4. 4.
    Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y. S., Wilschanski, M., Yaacov, Y. et al. (2007) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J. Clin. Invest. 117, 683–692.PubMedCrossRefGoogle Scholar
  5. 5.
    Zeitlin, P. L., Lu, L., Rhim, J., Cutting, G., Stetten, G., Kieffer, K. A. et al. (1991) A cystic fibrosis bronchial epithelial cell line: Immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 4, 313–319.PubMedGoogle Scholar
  6. 6.
    Yankaskas, J. R., Haizlip, J. E., Conrad, M., Koval, D., Lazarowski, E., Paradiso, A. M. et al. (1993) Papilloma virus immortalized tracheal epithelial cells retain a well-differentiated phenotype. Am. J. Physiol. 264, C1219–1230.Google Scholar
  7. 7.
    Lundberg, A. S., Randell, S. H., Stewart, S. A., Elenbaas, B., Hartwell, K. A., Brooks, M. W. et al. (2002) Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21, 4577–4586.PubMedCrossRefGoogle Scholar
  8. 8.
    Nissim-Rafinia, M., Aviram, M., Randell, S. H., Shushi, L., Ozeri, E., Chiba-Falek, O. et al. (2004) Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Rep. 5, 1071–1077.PubMedCrossRefGoogle Scholar
  9. 9.
    Linde, L., Boelz, S., Neu-Yilik, G., Kulozik, A. E., and Kerem, B. (2007) The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. Eur. J. Hum. Genet. 15, 1156–1162.PubMedCrossRefGoogle Scholar
  10. 10.
    Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M. et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 372, 719–727.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of GeneticsThe Life Sciences Institute, The Hebrew UniversityJerusalemIsrael

Personalised recommendations